ClinicalTrials.gg
Active, not recruitingNCT06390904Updated Aug 11, 2025

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

A Phase 2/3 interventional study of GnRH antagonist and Letrozole 2.5mg in Atypical Endometrial Hyperplasia, Progesterone Resistance and Obesity, sponsored by Xiaojun Chen. Active, not recruiting at 2 sites in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Xiaojun Chen · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jul 2022, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Endometrial Hyperplasia with a site in China — 14 open to participants now, 15 under way, 5 of them phase 3. Endometrial Hyperplasia · China.

Planned enrollment
16th of 19
29 · median 75
Started
2022
with 4 others
Phase 2/3
9 of 22
4 open now
Primary completion
2025-07
later than 0 of 14 live
Registered
14th of 22
by date
Lead sponsor
6 of 22
Xiaojun Chen

Among the 22 studies in Endometrial Hyperplasia with a site in China, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2022, is one of 9 in phase 2/3, reaches primary completion later than 0 of the 14 other live ones, and was the 14th registered.

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Open to participants now

14 of the 22 studies in Endometrial Hyperplasia with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Endometrial Hyperplasia with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.

Read the detailed description

There were more and more women with early endometrioid endometrial cancer (EEC) and atypical endometrial hyperplasia (EAH) who want to preserve fertility.

Approximately 70% to 80% of females who meet the criteria for conservation treatment are able to achieve complete response (CR) after progestin therapy, with a median time of 6-7 months, but about 20% to 30% of patients get no response or need to take longer time to achieve remission (over one year). With long duration of treatment, there will be more side effects such as weight gain, impaired liver function, endometrial injury, ovarian reserve inhibition etc. which will decrease the efficacy of conservative treatment. Previous researches had shown that Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole could be a better second-line treatment for obese progestin-insensitive patients. Till now, no similar studies were found, so the investigators design this study to explore the efficacy of GnRHa plus letrozole in obese progestin-insensitive EAH patients to provide new evidences for improving conservative treatment efficacy. The investigators defined obese patients as these with BMI ≥ 30kg/m\^2.

This will be a single-centred prospective pilot study. Patients diagnosed as obese progestin-insensitive EAH by dilatation and curettage (D\&C) or hysteroscopy will be enrolled. The primary endpoint is cumulative CR rate at 28 weeks of treatment. The secondary endpoints include adverse events, duration of complete response, recurrent rate, pregnancy rate and quality of life of patients.

03

Conditions studied

  • Atypical Endometrial Hyperplasia
  • Progesterone Resistance
  • Obesity
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove EAH
  • ≥30kg/m2
  • Using progestin, any of the following therapy, as treatment:

    1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not
    2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not
    3. LNG-IUS inserted
  • Progestin-insensitive:

    1. remained with stable disease after 7 months of progestin use
    2. did not achieve CR after 10 months of progestin use
  • Have a desire for remaining reproductive function or uterus
  • Good compliance with adjunctive treatment and follow-up

Exclusion criteria

Exclusion Criteria:

  • Combined with severe medical disease or severely impaired liver and kidney function
  • confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine
  • Patients with other types of endometrial cancer or other malignant tumors of the reproductive system
  • Patients with breast cancer or other hormone- dependent tumors or diseases that cannot be used with GnRHa or Letrozole
  • Strong request for uterine removal or other conservative treatment
  • Known or suspected pregnancy
  • Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
  • Smoker(>15 cigarettes a day)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    Obese EAH group

    This group including 29 EAH cases. Interventional Study Model was Simon two-stage optimal design. Eleven patients were needed for the first stage, and if eight or more patients achieved CR at 28 weeks, the trial can enter into the second stage. Then every 12 to 16 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.

    Drug: GnRH antagonist · Drug: Letrozole 2.5mg

Interventions

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate within 28 weeks of treatment

    The cumulative 28-week CR rate will be calculated. Patients will be evaluated with an hysteroscopy every 12 to 16 weeks. The response to progestin treatment was assessed histologically using specimens obtained during each hysteroscopic evaluation. CR was defined as the absence of hyperplasia or carcinoma.

    Time frame: Up to 28 weeks

Secondary outcomes

  1. Adverse events

    Adverse effects were recorded during the entire treatment period, including weight gain, thrombosis, lactic acidosis, abnormal liver and renal function, and other toxicities or complaints.

    Time frame: During the treatment period, an average of 28 weeks

  2. Time to achieve CR

    The median CR time will be calculated.

    Time frame: During the treatment period, an average of 28 weeks

  3. Relapse rate

    Relapse will be defined as endometrial hyperplasia or endometrial cancer recurred after patients achieve CR.

    Time frame: Average of 2 years after the completion of the treatment

  4. Rate of fertility outcomes

    Among patients prepared to get pregnant, fertility outcomes will be recorded.

    Time frame: Average of 2 years after the completion of the treatment

07

Study locations

2 sites
08

References and documents

Publications

  • Zhou S, Xu Z, Yang B, Guan J, Shan W, Shi Y, Chen X. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment. J Gynecol Oncol. 2021 Jul;32(4):e57. doi: 10.3802/jgo.2021.32.e57. PubMed 34085795 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jul 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 30, 2024
StartActual
Jul 13, 2022
Primary completionActual
Jul 30, 2025
CompletionEst.
Jul 30, 2027
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06390904
Lead sponsor
Xiaojun Chen
Responsible party
Xiaojun Chen (Professor, Fudan University) — Sponsor-investigator
First posted
Apr 30, 2024
Start date
Jul 13, 2022
Primary completion
Jul 30, 2025
Completion
Jul 30, 2027 (estimated)
Last update
Aug 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion